Affordable AI-Driven Blood Test Advances Lung Cancer Screening
A new study in Translational Lung Cancer Research introduces LungCanSeek, an AI-powered blood test that detects lung cancer early using four common protein markers, offering high accuracy at a fraction of the cost of traditional imaging. Developed by SeekIn Inc., the test achieves 83.5 percent sensitivity and 90.3 percent specificity in identifying lung cancer, with 77.4 percent accuracy in classifying major subtypes including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer. By enabling a two-step screening process—initial blood draw followed by low-dose CT only for positives—it slashes false positives by over tenfold and cuts costs by 2.5 times, positioning it as a viable tool for resource-limited settings worldwide. Study Design and Methodology The multicenter retrospective analysis, conducted by a team from prominent Chinese hospitals under the leadership of SeekIn’s founder, involved 1,814 participants, comprising 1,095 confirmed lung cancer patients…

